Académique Documents
Professionnel Documents
Culture Documents
emergency states:
AMI,
cerebral stroke,
pulmonary oedema
Unstable angina
necrosis
Cardiac biomarkers
Ecg
Echocardiography
Lipids
CBC -complete blood count
ECG
ST-segment elevation or presumed new LBBB is characterized by
ST-segment elevation >1 mm (0.1 mV) in 2 or more contignous
precordial leads or 2 or more adjacent limb leads and is classified as
ST-elevation MI (STEMI).
Ischemic ST-segment depression 0.5 mm (0.05 mV) or dynamic Twave inversion with pain or discomfort is classified as high-risk
UA/nonST-elevation MI (NSTEMI). Nonpersistent or transient STsegment elevation 0.5 mm for <20 minutes is also included in this
category.
Normal or nondiagnostic changes in ST segment or T waves are
inconclusive and require further risk stratification. This classification
includes patients with normal ECGs and those with ST-segment
deviation of <0.5 mm (0.05 mV) or T-wave inversion of 0.2 mV.
Serial cardiac studies (and functional testing) are appropriate.
Cardiac biomarkers
- creatine kinase (CK)
Elevation of the serum total CK is a sensitive enzymatic
detector of AMI
False positive resalts in patients with:
Muscle disease
Alcohol intoxication
DM
Skeletal muscle trauma
Vigorous exercise
Convulsion
Intramuscular injections
Pulmonary embolism
Three isoenzymes of CK: CK-BB (brain and kidney), CKMM (skeletal muscle) and CK-MB (heart)
A ratio (relative index) of CK-MB/total CK > 6% is
indicative of a myocardial rather then other source of the
CK-MB elevation
Cardiac biomarkers
- troponin
Best diagnostic and prognostic marker of AMI
The troponin complex consist of three subunits that
regulate the calcium mediated contractil process of
strited muscle. troponin I, T and C
Whereas CK-MB usually increases 10 to 20 fold above
the upper limit of the reference range, troponin T and I
typically increase more then 20 times above the
reference range. Troponin T and I are more sensitive in
diagnosis of minor myocardial damage
Troponin I and T gold standard in diagnosis of AMI
Cardiac biomarkers
- the level of troponin increase in
HF
Aortic aneurysm
Pulmonary embolism
Toxic injure of heart muscle (chemiotherapy)
miocarditis
Injury of heart muscle
Chronic renal failure
Acute abdominal problem
burns
other: kardioversion, arrhythmias
Cardiac biomarkers
- mioglobin
Early marker of necrosis
Hight negative prognostic value .
Reference range of mioglobin over 8 h
after chest pain exclude MI.
reference range <70- 110 ng/ml,
AMI: 600- 1000 ng/ml
Cardiac biomarkers
- the level of mioglobin increase in
Cardiac biomarkers
hFABP heart fatty acid binding proteins
Cardiac biomarkers
Marker
Range of times
to initial
elevation (h)
Mean time to
peak elevation
(h)
Time to return
to normal range
hFABP
Mioglobin
Troponin T
Troponin I
CK-MB
1.5
1-4
3-12
3-12
3-12
5-10
6-7
24h-2d
24h
24
24h
24h
5-14d
5-10d
48-72h
M
O
N
A
ECG
Establish iv access
Administer MONA
M morphine iv if
pain not relieved by
nitroglycerine
O oxygen at 4l/min
N nitroglycerine
sublingual, spray or
iv
A aspirine 300mg
out-of-hospital fibrinolysis
In summary, out-of-hospital administration of fibrinolytics to
patients with STEMI with no contraindications is safe,
feasible, and reasonable (Class IIa).
The ECC Guidelines 2005 recommended consideration
of out-of-hospital fibrinolysis for patients with a transport
time >1 hour.
But in a recent Swiss study, prehospital administration of
fibrinolytics significantly decreased the time to drug
administration even in an urban setting with relatively
short transport intervals (<15 minutes).
Fibrinolytic Therapy:
Contraindications and Cautions for Fibrinolytic Use in
STEMI From ACC/AHA 2004 Guideline Update
Absolute Contraindications
Any prior intracranial hemorrhage
Known structural cerebral vascular lesion
(eg, AVM)
Known malignant intracranial neoplasm
(primary or metastatic)
Ischemic stroke within 3 months EXCEPT
acute ischemic stroke within 3 hours
Suspected aortic dissection
Active bleeding or bleeding diathesis
(excluding menses)
Significant closed head trauma or facial
trauma within 3 months
Relative Contraindications
History of chronic, severe, poorly
controlled hypertension
Severe uncontrolled hypertension on
presentation (SBP >180 mm Hg or
DBP>110 mm Hg)
History of prior ischemic stroke _3
months, dementia, or known intracranial
pathology not covered in contraindications
Traumatic or prolonged (>10 minutes)
CPR or major surgery (<3 weeks)
Recent (within 2 to 4 weeks) internal
bleeding
Noncompressible vascular punctures
For streptokinase/anistreplase: prior
exposure (>5 days ago) or prior allergic
reaction to these agents
Pregnancy
Active peptic ulcer
Current use of anticoagulants: the higher
the INR, the higher the risk of bleeding
In hospital treatment
STEMI
Reperfusion
pharmacologic fibrinolytic therapy
mechanical primary PCI (percutaneous coronary intervention)
NSTEMI
fibrinolysis may be harmful
Pharmaclologic therapy:
cerebral stroke
Stroke -Definition
Stroke is defined as a sudden neurologic
deficit due to central nervous ischaemia or
haemorrhage.
We concentrate here on ischaemic stroke, which
accounts for about 75% of all strokes.
4 Pulse oxymetry
Treatment
1. Continuous cardiac monitoring is recommended in the first 48 h of stroke onset
particularly in patients with:
1.
2.
3.
4.
5.
6.
Treatment
8. Recommended drugs for blood pressure treatment:
intravenous labetalol or urapidil and
intravenous sodium nitroprusside, nitroglycerin or oral captopril.
Avoid nifedipine and any drastic blood pressure decrease.
Treatment
14. Immediate correction of hypoglycaemia is
recommended by intravenous dextrose bolus or
infusion of 1020% glucose.
15. Treatment of body temperature >37.5 C
Specific Treatment
Thrombolytic Therapy
1. Intravenous rtPA (0.9 mg/kg, maximum 90 mg), with 10% of the dose
given as a bolus followed by an infusion lasting 60 min, is the
recommended treatment within 3 h of onset of ischaemic stroke.
2. The benefit from the use of intravenous rtPA for acute ischaemic stroke
beyond 3 h after onset of the symptoms is smaller, but present up to
4.5 h.
3. Intravenous rtPA is not recommended when the time of onset of stroke
cannot be ascertained reliably; this includes persons whose strokes are
recognised upon awakening.
4. Intravenous administration of streptokinase is dangerous and not
indicated for the management of persons with ischaemic stroke.
5. Data on the efficacy and safety of any other intravenously administered
thrombolytic drugs are not available to provide a recommendation.
6. Intra-arterial treatment of acute MCA occlusion in a 6-hour time window
using pro-urokinase results in a significantly improved outcome.
7. Acute basilar occlusion may be treated with intra-arterial therapy in
selected centres in an institutional protocol as experimental therapy or
within a multicentre clinical trial.
8. Ancrod cannot presently be recommended for use in acute ischaemic
stroke outside the setting of clinical trials.
Specific Treatment
Aspirin (100300 mg per day) may be given within 48 h after ischaemic stroke
given within 48 h after stroke reduces mortality and rate of recurrent stroke minimally, but
statistically significantly
If thrombolytic therapy is planned, no aspirin should be given.
Aspirin is not allowed for 24 h after thrombolytic therapy.
Full-dose heparin may be used when there are selected indications such as cardiac sources
with high risk of re-embolism, arterial dissection, or high-grade arterial stenosis prior to
surgery
Low-dose subcutaneous heparin or low-molecular-weight heparins should only be
considered for patients at high risk of DVT or pulmonary embolism.
Prophylactic administration of anticonvulsants to patients with recent stroke who have not
had seizures is not recommended
pulmonary oedema
heart failure
- common causes of HF
Heart feilure is a
result of acute pump
dysfunction
IHD
Valvular disfunctin
Cardiomyopathy
Acquired cardiomyopathy
(toxic-alcohol, cocain; or
metabolic
thyreotoxicosis)
Myocarditis
Constrictive pericarditis
Cardiac tamponade
Systemic hypertension
Other anemia, cardiac
dysrhythmias
heart failure
- diagnosis
Echocardiography gold standard
Chest X-ray
Natriuretic peptide (BNP)
blood
NT-proBNP (76 amino acids)
Morphine
Indication
Early stages of AHF treatment, especially
when
associated with restlessness and dyspnea
Effects
Venodilation & mild arterial vasodilation
heart rate
Dosing
3 mg boluses, which can be repeaded
Anticoagulation
Indication
Well established in ACS or AFib, with or without AHF
Less evidence in AHF
Administration
Careful monitoring of coagulation system
If Creatinine Clearance < 30 mL/min - Contraindicated or used
with extreme care with anti-Factor Xa level monitoring
Diuretics
Indication
Patients with AHF & ADHF with symptoms secondary to fluid retention
Effects
Diuresis by water, NaCl & other ions excretion
total body water & Na
plasma & EC volume
RV & LV filling pressures
peripheral congestion & pulmonary edema